TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

Telix Pharmaceuticals announced publication of ProstACT SELECT Phase 1 study results in peer-reviewed journal Cancers, demonstrating that 68Ga-PSMA-PET imaging can reliably identify patients suitable for TLX591-Tx therapy. The study showed TLX591-Tx achieved a median radiographic progression-free survival of 8.8 months with a manageable safety profile in advanced metastatic prostate cancer patients, supporting the ongoing Phase 3 ProstACT Global trial.